Is Skyrizi approved for treating psoriatic arthritis?
Yes, Skyrizi was approved in January 2022 to treat psoriatic arthritis in adults. Skyrizi was also approved in April 2019 to treat moderate-to-severe plaque psoriasis in adults. A third indication, moderate-to-severe Crohn's disease in adults, was cleared by the FDA in June 2022.
The Skyrizi (risankizumab-rzaa) approval for psoriatic arthritis was supported by two Phase 3, placebo controlled studies, KEEPsAKE-1 and KEEPsAKE-2.
Psoriatic arthritis is an inflammatory arthritis associated with plaque psoriasis. Over 30% to 40% of people with plaque psoriasis may develop psoriatic arthritis. Common symptoms are pain, swelling and stiffness, fatigue and loss of ability to fully use the joint.
Other treatments approved by the FDA to treat psoriatic arthritis include:
This is not all the information you need to know about Skyrizi for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Skyrizi product information here, and discuss this and any questions you have with your doctor or other health care provider.
Related medical questions
- Does Skyrizi cause cancer?
- Skyrizi vs Humira for plaque psoriasis - How do they compare?
- Is Skyrizi approved for treating psoriatic arthritis?
- Who makes Skyrizi and where is it made?
- Skyrizi vs Ilumya. What’s the difference?
- Does Skyrizi cause cancer?
- Skyrizi vs Humira for plaque psoriasis - How do they compare?
- Is Skyrizi approved for treating psoriatic arthritis?
- Who makes Skyrizi and where is it made?
- Skyrizi vs Ilumya. What’s the difference?
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions